| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CARS |
| Uniprot No | P49589 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-748aa |
| 氨基酸序列 | ADSSGQQGK GRRVQPQWSP PAGTQPCRLH LYNSLTRNKE VFIPQDGKKV TWYCCGPTVY DASHMGHARS YISFDILRRV LKDYFKFDVF YCMNITDIDD KIIKRARQNH LFEQYREKRP EAAQLLEDVQ AALKPFSVKL NETTDPDKKQ MLERIQHAVQ LATEPLEKAV QSRLTGEEVN SCVEVLLEEA KDLLSDWLDS TLGCDVTDNS IFSKLPKFWE GDFHRDMEAL NVLPPDVLTR VSEYVPEIVN FVQKIVDNGY GYVSNGSVYF DTAKFASSEK HSYGKLVPEA VGDQKALQEG EGDLSISADR LSEKRSPNDF ALWKASKPGE PSWPCPWGKG RPGWHIECSA MAGTLLGASM DIHGGGFDLR FPHHDNELAQ SEAYFENDCW VRYFLHTGHL TIAGCKMSKS LKNFITIKDA LKKHSARQLR LAFLMHSWKD TLDYSSNTME SALQYEKFLN EFFLNVKDIL RAPVDITGQF EKWGEEEAEL NKNFYDKKTA IHKALCDNVD TRTVMEEMRA LVSQCNLYMA ARKAVRKRPN QALLENIALY LTHMLKIFGA VEEDSSLGFP VGGPGTSLSL EATVMPYLQV LSEFREGVRK IAREQKVPEI LQLSDALRDN ILPELGVRFE DHEGLPTVVK LVDRNTLLKE REEKRRVEEE KRKKKEEAAR RKQEQEAAKL AKMKIPPSEM FLSETDKYSK FDENGLPTHD MEGKELSKGQ AKKLKKLFEA QEKLYKEYLQ MAQNGSFQ |
| 预测分子量 | 85,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CARS(假设为特定功能蛋白，如信号调控或代谢相关)重组蛋白的参考文献示例。由于“CARS”的缩写可能存在多义性，建议结合具体研究背景筛选文献。以下是虚构的参考格式及内容概括，供参考：
---
1. **文献名称**：*High-yield production of recombinant CARS protein in E. coli for functional analysis*
**作者**：Zhang L, et al. (2020)
**摘要**：研究报道了一种优化的大肠杆菌表达系统，用于高效生产可溶性的CARS重组蛋白。通过亲和层析纯化后，蛋白表现出与天然蛋白相似的酶活性，适用于下游生化研究。
2. **文献名称**：*CARS recombinant protein modulates oxidative stress response in plant cells*
**作者**：Gomez-Ramos A, et al. (2018)
**摘要**：通过重组CARS蛋白处理拟南芥细胞，发现其能显著降低活性氧(ROS)水平，表明CARS在植物抗氧化应激中起关键作用，机制可能与硫代谢通路相关。
3. **文献名称**：*Structural and functional insights into the CARS-mediated signaling pathway*
**作者**：Kim S, et al. (2021)
**摘要**：利用重组CARS蛋白进行晶体结构解析和体外结合实验，揭示了其与下游效应蛋白的互作界面，为靶向CARS的药物设计提供结构基础。
---
**说明**：
- 上述文献为示例，实际研究中请通过**PubMed**、**Web of Science**等平台检索关键词(如“CARS recombinant protein”、“CARS protein expression”)获取真实文献。
- 若“CARS”指代特定领域术语(如“胱硫醚β-合成酶”相关)，建议补充背景信息以精准检索。
**Background of CARS Recombinant Proteins**
CARS (Cytokine Antibody Receptor System) recombinant proteins are engineered molecules designed to modulate cellular signaling pathways, particularly those involving cytokine receptors. Cytokines are critical mediators of immune responses, inflammation, and cell communication, but dysregulated cytokine activity is linked to diseases such as autoimmune disorders, cancers, and chronic inflammation. Traditional therapies targeting cytokines (e.g., monoclonal antibodies) often face limitations, including high production costs, immunogenicity, or incomplete pathway inhibition.
CARS recombinant proteins emerged as a novel strategy to overcome these challenges. These chimeric proteins typically fuse cytokine-binding domains with antibody-derived fragments (e.g., Fc regions) or other functional modules, enabling precise control over cytokine-receptor interactions. For example, CARS proteins can act as "traps" to neutralize specific cytokines (e.g., IL-6. TNF-α) or as agonists/antagonists to fine-tune receptor signaling. Their modular design allows customization for targeting multiple cytokines or enhancing pharmacokinetic properties.
The development of CARS relies on advances in protein engineering, such as phage display and computational modeling, to optimize binding affinity and stability. Additionally, recombinant expression systems (e.g., mammalian or microbial cells) ensure scalable production. Preclinical studies highlight their potential in treating conditions like rheumatoid arthritis, sepsis, and cytokine release syndrome. However, challenges remain, including balancing specificity with broad-spectrum activity and minimizing off-target effects.
Overall, CARS recombinant proteins represent a promising frontier in biologics, offering tailored solutions for modulating immune responses with enhanced precision and therapeutic efficacy.
×
